Literature DB >> 16388358

Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis.

E Capello1, R Saccardi, A Murialdo, F Gualandi, F Pagliai, A Bacigalupo, A Marmont, A Uccelli, M Inglese, P Bruzzi, M P Sormani, E Cocco, G Meucci, L Massacesi, A Bertolotto, A Lugaresi, E Merelli, A Solari, M Filippi, G L Mancardi.   

Abstract

Aggressive forms of multiple sclerosis (MS) represent a limited group of demyelinating diseases that rapidly progress to severe disability. Currently available therapies are poorly effective against these clinical entities. Recently, it has been demonstrated that intense immunosuppression followed by autologous haematopoietic stem cell transplantation (AHSCT) can affect the clinical course of individuals with severe MS and completely abrogate the inflammatory activity detected by MRI. We report the result of the Italian phase 2 GITMO study, a multicentre study in which 21 MS patients, who were rapidly deteriorating and not responding to the usual therapeutic strategies, were treated with this procedure. The clinical effect of the treatment is long lasting, with a striking abrogation of inflammation detected by MRI findings. These results support a role for intense immunosuppression followed by ASCT as treatment in rapidly evolving MS cases unresponsive to conventional therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388358     DOI: 10.1007/s10072-005-0514-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  8 in total

1.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

2.  Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.

Authors:  Nuria Sola-Valls; María Sepúlveda; Yolanda Blanco; Albert Saiz
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

Review 3.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.

Authors:  Marcelo C Pasquini; Linda M Griffith; Douglas L Arnold; Harold L Atkins; James D Bowen; Jacqueline T Chen; Mark S Freedman; George H Kraft; Gian Luigi Mancardi; Roland Martin; Paolo A Muraro; Richard A Nash; Michael K Racke; Jan Storek; Riccardo Saccardi
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-18       Impact factor: 5.742

Review 4.  New approaches in the management of multiple sclerosis.

Authors:  Laurie J Barten; Douglas R Allington; Kendra A Procacci; Michael P Rivey
Journal:  Drug Des Devel Ther       Date:  2010-11-24       Impact factor: 4.162

Review 5.  Cell Therapy for Multiple Sclerosis.

Authors:  Pamela Sarkar; Claire M Rice; Neil J Scolding
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 6.497

6.  The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.

Authors:  A G Willison; T Ruck; G Lenz; H P Hartung; S G Meuth
Journal:  J Neurol       Date:  2022-04-11       Impact factor: 4.849

Review 7.  Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.

Authors:  Maria Teresa Cencioni; Angela Genchi; Gavin Brittain; Thushan I de Silva; Basil Sharrack; John Andrew Snowden; Tobias Alexander; Raffaella Greco; Paolo A Muraro
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

Review 8.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.